Skip to main content
. 2020 Sep 1;12(9):2483. doi: 10.3390/cancers12092483

Figure 3.

Figure 3

ATO/Lena inhibited NF-κB activation and increased KSHV reactivation in ex vivo treated ascites-derived BC-3 and BCBL-1 cells. (a) Western blot analysis of p-IκBα in ATO/Lena ex vivo treated ascites-derived BC-3 and BCBL-1 cells 48 h post treatment. Confocal microscopy analysis of p65 nuclear translocation in ascites-derived BC-3 and BCBL-1 after ex vivo treatment with ATO/Lena for 48 h. p65 was stained with anti-p65 antibody (red) and nuclei were stained by Hoechst stain (blue). Images represent z-sections. Histograms represented number of cells with nuclear p65 translocation. Uncropped blots of Figure 3a are shown in Figure S5. (b) Real-time quantitative PCR showing transcript levels of human IL-6 and IL-10 cytokines in ascites-derived BC-3 (left) and BCBL-1 (right) cells 48 h following ex vivo treatment with ATO and/or Lena. (c,d) Real-time quantitative PCR analysis of transcript levels of KSHV early-lytic genes (RTA, ORFK8) (c) or late lytic gene (K8.1) (d) in ascites-derived BC-3 (left) and BCBL-1 (right) cells after ex vivo treatment with ATO and/or Lena for 24 (c) or 48 h (d) as indicated. Results represent the average of 3 independent experiments. (*) indicates p < 0.05; (**) indicates p < 0.01; and (***) indicates p < 0.001.